UBS cuts target to USD 400 for Cencora stock

Published on 10/20/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS cut its target to USD 400 from USD 430 on October 16, 2026. Cencora stock faces November 4 results and USD 17.75-17.95 adjusted EPS guidance.

Targets and operating scale

UBS cut its Cencora target from USD 430 to USD 400 on October 16, 2026.
Fiscal third-quarter revenue reached USD 84.75 billion on June 30, 2026.
Cencora stock traded at EUR 303.50 at 10:38 a.m. CEST at Lang & Schwarz on October 20, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. (ISIN US03073E1055) stock was trading at EUR 303.50 at Lang & Schwarz at 10:38 a.m. CEST on October 20, 2026. UBS cut its price target from USD 430 to USD 400 and kept a Buy rating on October 16, 2026, as Yahoo Finance reported.

Three targets frame the stock

The UBS reduction was the latest of three dated analyst actions highlighted in the recent Cencora coverage. On October 7, 2026, Leerink Partners raised its target from USD 380 to USD 388, while Baird raised its target from USD 370 to USD 373 on October 12, 2026, according to MarketScreener. UBS then cut its target from USD 430 to USD 400 on October 16, 2026, according to Yahoo Finance.

What does the guidance mean?

The operating picture remains tied to the fiscal third-quarter report. Cencora reported USD 84.75 billion in revenue for the quarter ended June 30, 2026, up 5.10 percent from the prior-year period, while diluted earnings per share reached USD 3.94, according to the Benzinga transcript. Management raised fiscal 2026 adjusted earnings-per-share guidance to USD 17.75-17.95 from USD 17.70-17.90.

Next date is November 4

Cencora plans to release fiscal fourth-quarter 2026 results before the New York Stock Exchange opens on November 4, 2026, followed by an earnings call at 8:30 a.m. ET. The company announced the schedule on October 2, 2026, in a release carried on its investor site.

Price and valuation context

Cencora's market capitalization was USD 64.9 billion on October 19, 2026, while its 52-week range was USD 244.82 to USD 377.54. The company operates in healthcare distribution and supplies pharmaceutical products and related services to providers, manufacturers and pharmacies.

The stock was trading at EUR 303.50 at Lang & Schwarz on October 20, 2026 at 10:38 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.